The FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026, replacing the old Quality System Regulation (QSR) that had governed 21 CFR Part 820 since 1996. The regulation number stayed the same — 21 CFR Part 820 — but the substance changed significantly. The core shift: the FDA incorporated ISO 13485:2016 by reference, making it the backbone of U.S. medical device quality system requirements for the first time. For manufacturers already certified to ISO 13485, many obligations now overlap with FDA expectations. For those who were not, the QMSR represents a broader set of documented requirements than the old QSR demanded.

What the QMSR actually is

The QMSR is the revised version of 21 CFR Part 820. The FDA published the final rule on February 2, 2024, giving manufacturers exactly two years to prepare before enforcement began. The rule did not create a new regulation from scratch. It amended the existing Part 820 by incorporating ISO 13485:2016 and ISO 9000:2015 Clause 3 (definitions) by reference, while adding FDA-specific requirements where ISO 13485 alone was insufficient to meet the statutory expectations of the Federal Food, Drug, and Cosmetic Act.

The old regulation was informally called the Quality System Regulation or QSR. The revised version carries a new name: the Quality Management System Regulation, or QMSR. The underlying legal authority — Section 520(f) of the FD&C Act — did not change. What changed is how the FDA defines what a compliant quality system looks like in practice.

According to the FDA’s QMSR page, the agency determined that ISO 13485:2016 requirements are, taken in totality, substantially similar to the old QSR requirements, providing an equivalent level of assurance that devices are manufactured safely and consistently.

What changed from the old QSR

Incorporation of ISO 13485:2016

The most consequential change is structural. Under the old QSR, the FDA maintained its own standalone quality system requirements. Under the QMSR, ISO 13485:2016 is incorporated by reference, meaning compliance with the QMSR requires compliance with ISO 13485 unless FDA-specific provisions say otherwise. Manufacturers can access the standard in read-only format through the ANSI Incorporated by Reference Portal at ibr.ansi.org.

This harmonization aligns the U.S. with regulatory authorities in Canada, the European Union, Japan, and other markets that have used ISO 13485 as the baseline standard for years. A manufacturer certified to ISO 13485:2016 by an accredited certification body will find that a large portion of their existing documentation already addresses QMSR obligations, though FDA-specific additions still apply.

Expanded FDA inspection authority

Under the old QSR, Section 820.180(c) exempted internal quality audits from FDA inspection — including supplier audits and management review reports. The QMSR eliminates this exemption entirely.

As of February 2, 2026, FDA investigators can request and review:

• Internal audit reports
• Supplier audit reports and findings
• Management review meeting records and outputs

The FDA’s rationale, stated in the final rule preamble, is that manufacturers already provide these records to other regulatory bodies under ISO 13485, so making them available to FDA investigators does not create additional burden. For manufacturers whose internal audits have historically been informal or underdocumented, this change creates a real compliance gap. An audit trail that shows systematic, structured internal reviews is now essential to inspection readiness.

New inspection process replacing QSIT

The Quality System Inspection Technique (QSIT), which FDA investigators used for decades to structure device inspections, was withdrawn on February 2, 2026. The new inspection process is described in the updated Compliance Program 7382.850 (Inspection of Medical Device Manufacturers), implemented on the same date the QMSR took effect.

Manufacturers preparing for their first post-QMSR inspection should review this compliance program and understand how their quality system documentation maps to QMSR requirements rather than the old QSIT subsystem framework.

Combination product requirements clarified

The FDA also made conforming edits to 21 CFR Part 4 to clarify quality management system requirements for combination products (devices combined with drugs or biologics). These edits did not change the underlying CGMP requirements for combination products but provide additional clarity for manufacturers operating at the device-drug or device-biologic boundary.

What stayed the same

The fundamental obligations of a quality management system for medical devices did not change. Manufacturers must still:

• Establish, document, implement, and maintain a quality management system
• Define and control processes for design, production, and post-market activities
• Conduct internal audits at planned intervals
• Control nonconforming products and initiate corrective and preventive actions
• Maintain document and record control systems
• Qualify and monitor suppliers

The FDA was explicit in the final rule: the requirements of the QSR and the QMSR are substantially similar. A manufacturer that maintained a well-run quality system under the old regulation should find the transition manageable. Records created before February 2, 2026 remain valid, and the FDA has indicated that investigators may find it useful when manufacturers complete a comparative analysis showing that pre-QMSR records meet QMSR requirements.

The statutory basis and enforcement authority also stayed the same. The FDA still conducts risk-based inspections. A FDA Form 483 observation under the QMSR carries the same weight as it did under the old QSR. The path from inspection observation to warning letter to consent decree follows the same escalation pattern.

MDSAP (Medical Device Single Audit Program) continues as a voluntary third-party audit program. Holding an MDSAP certificate does not exempt a manufacturer from FDA inspection, and the FDA will not issue ISO 13485 certificates of conformance. FDA inspections assess compliance with federal regulations; third-party MDSAP audits assess conformance to the ISO standard.

What the QMSR means for ISO 13485-certified manufacturers

If your facility holds a current ISO 13485:2016 certification, a significant portion of your quality system already aligns with QMSR requirements. The areas to examine carefully are the FDA-specific additions: requirements that clarify expectations beyond what ISO 13485 alone specifies, particularly around electronic records under 21 CFR Part 11, combination product documentation, and the now-eliminated inspection exemptions for audits and management reviews.

ISO 13485 certification is not a substitute for QMSR compliance, and the FDA will not accept a certification certificate as evidence of compliance. The FDA’s inspection program operates independently from third-party certification schemes.

What the QMSR means for manufacturers who were not ISO 13485-certified

The transition is more substantial for facilities that built their quality systems to the minimum QSR requirements without pursuing ISO 13485 certification. ISO 13485 is more prescriptive in certain areas — particularly risk management integration, supplier qualification, and formal management review documentation.

Areas that commonly require additional work include:

• Risk management documentation and integration with design and production processes
• Supplier qualification and audit programs (now fully subject to FDA inspection)
• Formal management review records with documented outputs and follow-up actions
• Process validation with documented evidence across all production stages

The two-year transition period from February 2024 to February 2026 was intended to allow manufacturers to close these gaps. Manufacturers still working through their gap analysis should prioritize the areas most likely to surface during an inspection visit: internal audit records, supplier controls, management review minutes, and corrective action systems.

How an eQMS supports QMSR compliance

The shift to QMSR compliance is, at its core, a documentation and traceability challenge. Every process change, corrective action, audit finding, supplier evaluation, and management review decision must be recorded, controlled, and available for review on demand.

Paper-based or fragmented quality systems create serious risk in this environment. When an FDA investigator arrives and requests your supplier audit reports from the past three years, a quality management system that stores documents in shared drives or physical binders cannot produce them quickly or consistently.

Cloudtheapp’s cloud-based eQMS is built for exactly this operating model. With 60+ purpose-built applications covering audits, supplier qualification, CAPA, document control, and management review, Cloudtheapp gives quality teams a single source of truth for every record that matters under the QMSR. The platform is validated to FDA computer system validation guidelines and supports 21 CFR Part 11 electronic records and signatures, so your digital records meet the same evidentiary standards as paper records in an FDA inspection.

Manufacturers transitioning from the old QSR to the QMSR use Cloudtheapp to map their existing quality system documentation against QMSR requirements, identify gaps, and build the processes needed to close them — without rebuilding their system from scratch.

See how Cloudtheapp supports QMSR compliance

Common questions about 21 CFR Part 820 and the QMSR

Does 21 CFR Part 820 still exist?

Yes. The regulation number 21 CFR Part 820 did not change. The QMSR is the updated version of Part 820, published under the same citation. References to “21 CFR Part 820” after February 2, 2026 refer to the QMSR.

When did the QMSR become mandatory?

February 2, 2026. The final rule was published on February 2, 2024, and the two-year transition period ended on the effective date. FDA inspections conducted on or after that date assess compliance with the QMSR, not the old QSR.

Do I need ISO 13485 certification to comply with the QMSR?

No. ISO 13485 certification from a third-party body is voluntary. The QMSR incorporates ISO 13485:2016 requirements by reference as the substantive content of the regulation. You must meet those requirements, but the FDA does not require a third-party certificate.

What happened to the QSIT inspection process?

The Quality System Inspection Technique (QSIT) was withdrawn on February 2, 2026. FDA device inspections now follow the updated Compliance Program 7382.850.

Can FDA now inspect my internal audit records?

Yes. The exemption that previously protected internal quality audits, supplier audits, and management review reports from FDA inspection was eliminated under the QMSR. These records are now subject to review during FDA device inspections.

Conclusion

The QMSR kept the same regulation number but changed the underlying framework in ways that matter for daily quality operations. ISO 13485:2016 is now legally embedded in 21 CFR Part 820. Internal audits and management reviews are fully visible to FDA investigators. A new inspection process governs how those investigations unfold.

Manufacturers with well-documented quality systems built on ISO 13485 are in a strong position. Those whose quality systems were structured around the minimum QSR requirements have more work ahead, particularly in supplier qualification, audit documentation, and risk management.

The practical path forward is a documented gap analysis against QMSR requirements, followed by a systematic plan to close the identified gaps before your next FDA inspection visit. An eQMS like Cloudtheapp makes that process faster and gives you the documentation infrastructure to sustain it.

Request a demo to see how Cloudtheapp supports QMSR compliance

This post created by and appeared first on Cloudtheapp

Design control is the set of documented procedures, reviews, and records that govern how a medical device is designed, developed, and transferred to manufacturing. It exists because the FDA determined — after a series of device failures in the 1980s tied directly to design deficiencies — that many safety problems could be prevented if manufacturers followed a structured development process rather than designing ad hoc and testing late.

The original requirement appeared in 21 CFR Part 820.30, the Design Controls section of the Quality System Regulation (QSR), which took effect in 1996. On February 2, 2026, the FDA's Quality Management System Regulation (QMSR) replaced the QSR, aligning U.S. device requirements with ISO 13485:2016. Under the QMSR, design control requirements now map to ISO 13485 Clause 7.3 (Design and Development) rather than the prescriptive text of 820.30.

The substance of what FDA expects from design control programs has not changed significantly. The structure for demonstrating compliance has.

Who Must Follow Design Control Requirements

Under the old QSR's 820.30, design control applied to Class II and Class III devices and certain Class I devices. The QMSR and ISO 13485:2016 take a risk-based approach: design control requirements apply to any medical device where the design and development process could affect product safety, performance, or regulatory compliance.

In practice, this means most manufacturers of finished devices need documented design controls. Contract manufacturers who build to a customer-supplied design may be exempt from design control requirements for that specific product, but they must document the determination. The exemption is not assumed.

The Eight Elements of Design Control

Whether you are working under the old 820.30 or the current QMSR and ISO 13485:2016, the core elements of a design control system remain consistent.

Design and Development Planning requires a documented plan that identifies the activities required to complete the design, assigns responsibilities, and accounts for how the design interfaces with other products or systems. The plan must be updated as the design evolves. A static plan written at project kickoff and never revised is a documentation gap that FDA investigators note consistently.

Design Inputs are the documented requirements the device must meet. These include intended use, user needs, performance specifications, safety requirements, applicable standards, and regulatory requirements. Poorly defined inputs are the upstream cause of most design verification failures. If the inputs do not capture what the device actually needs to do, verification testing that confirms conformance to those inputs proves less than it appears to.

Design Outputs are the translated results of the design process: drawings, specifications, procedures, and software code. Each output must reference the input it satisfies, which is the foundation of design traceability. Under ISO 13485 Clause 7.3.4, design outputs must be in a form that allows verification against design inputs before release.

Design Review is a formal, documented examination at defined stages of the design process. It must include at least one individual who is not directly responsible for the design being reviewed. Design reviews evaluate whether the design meets its inputs, identify problems, and drive resolution before the project advances. Reviews that happen but are not documented — or that are documented as "no issues identified" without supporting records — generate audit findings during FDA inspections.

Design Verification confirms that the design output meets the design input. This is the "did we build it right" question. Verification typically involves testing, analysis, inspection, or comparison to a proven design. The verification protocol defines what will be tested, acceptance criteria, and sample sizes. When verification fails, the finding should feed back into the risk register and trigger a design change process.

Design Validation confirms that the finished device meets user needs and intended uses under actual or simulated use conditions. This is the "did we build the right thing" question. Validation must be performed on production-representative units. Validation on engineering prototypes does not satisfy the requirement. Under ISO 13485 Clause 7.3.6, software used in medical devices requires validation appropriate to its intended use and safety classification.

Design Transfer documents the process for moving the validated design into production. Transfer activities confirm that the production process can consistently produce a device that meets the design specifications. Transfer records connect the design outputs to the production documentation — drawings, work instructions, inspection criteria, and process parameters.

Design Changes require documented procedures for reviewing, approving, and implementing any change after design freeze. Under ISO 13485 Clause 7.3.9, changes must be evaluated for their effect on the complete device and on previously completed verification and validation activities. A change that affects a previously validated interface or safety-related function requires re-validation of the affected elements, not just re-testing.

What Changed Under FDA QMSR

The QMSR, effective February 2, 2026, incorporated ISO 13485:2016 by reference. This means FDA inspectors now evaluate design control compliance against ISO 13485 Clause 7.3 language rather than the specific text of 820.30.

Several practical differences follow from this shift.

The old 820.30 required a Design History File (DHF) — a compilation of records that describes the design history of a finished device. ISO 13485 Clause 7.3 does not use the term DHF, but FDA's QMSR final rule confirmed that FDA-specific requirements, including the DHF obligation, are maintained through supplemental requirements in the regulation. Manufacturers still need to maintain a DHF.

ISO 13485 Clause 7.3 introduces an explicit requirement for documented design and development inputs that include applicable regulatory requirements — a consideration for devices that need to comply with EU MDR, Canada's CMDR, or other international frameworks alongside U.S. requirements. For companies selling into multiple markets, design inputs that explicitly map to each applicable regulation simplify market-specific submission documentation.

The QMSR also strengthened the connection between design control and risk management. Under QMSR, ISO 14971 risk management outputs must be integrated into the design control process throughout development — not treated as a separate activity completed before design freeze. Design reviews must consider risk management outputs. Verification and validation activities must cover safety-critical functions identified in the risk analysis.

FDA Inspection Patterns for Design Controls

Design controls ranked as the second most frequently cited area in FDA device inspections in 2025, according to Hogan Lovells' September 2025 analysis of inspection trends. CAPA ranked first, and the two are closely connected: unresolved design control gaps frequently generate CAPAs, and CAPA investigations often surface design control deficiencies that were not previously documented.

The patterns FDA investigators find most often in design control programs:

Traceability gaps between design inputs and outputs are the single most common finding. Companies produce verification test reports but cannot show which input requirement each test was designed to verify. The traceability matrix either does not exist or was built after the fact and does not reflect the actual testing sequence.

Incomplete Design History Files are cited regularly, particularly in companies that manage design documentation across multiple systems — a PLM tool, a shared drive, and a paper archive. When an investigator requests the DHF and receives a partial compilation, the response "the rest is in the other system" is not sufficient. The DHF must be a coherent, accessible compilation.

Design changes processed outside the formal change control procedure appear in inspection records when companies make field corrections, software patches, or label changes without running those changes through the design control process. Under QMSR, any change to a previously validated design element requires documented evaluation and, where the change affects validated performance, re-validation.

Validation on non-representative units continues to be cited. Companies run final validation testing on hand-built or pre-production units and do not repeat or bracket the testing once manufacturing processes are finalized.

The Design History File: What Must Be in It

The DHF is not a single document. It is a compilation of records that, taken together, tells the complete story of how the device was designed and confirmed to meet its requirements.

A complete DHF includes the design and development plan, design input specifications, design output documentation, design review records, verification protocols and results, validation protocols and results, design transfer records, and all design change records from initial design through product release. Risk management records — per ISO 14971 — should also be referenced or included.

For companies managing DHFs in paper or disconnected electronic systems, the effort required to compile and present the DHF during an inspection is significant. The DHF must be produced quickly when requested. A two-day delay in assembling records creates its own impression during an inspection, separate from the content of the records themselves.

Managing Design Controls in an Electronic QMS

Design control in an electronic QMS connects planning documents, input specifications, output records, review sign-offs, verification and validation results, and change requests in a single traceable system. When a design input changes, the linked verification records receive an automatic notification. When a design change is submitted, the system identifies every downstream document that references the changed element.

This is the difference between traceability that exists as a spreadsheet maintained by one engineer and traceability that the system enforces by structure. During an FDA inspection, the ability to pull a complete, time-stamped, electronically signed DHF in minutes — rather than hours — directly affects how the inspection proceeds.

Cloudtheapp's Design Controls application connects inputs, outputs, reviews, and change management into a single workflow with full audit trail. Verification and validation records link directly to the design inputs they address. Request a demo at cloudtheapp.com/demo/ to see how the system handles DHF compilation and design change traceability.

The Inspection Question You Want to Be Ready For

FDA investigators ask one question in almost every device inspection that involves design controls: "Can you show me the traceability from your design inputs to your verification testing?"

Companies that answer this by opening a spreadsheet and scrolling through rows are spending inspection time explaining gaps. Companies that answer it by opening a QMS and pulling a linked traceability matrix in 30 seconds are moving on to the next question.

The design control requirement has not changed materially under QMSR. What the QMSR changed is the framework language and the explicit integration of risk management throughout the design process. For companies already running a mature ISO 13485 design control program, the transition to QMSR compliance is largely administrative. For companies that built their design control system around the specific text of 820.30 and never updated it to align with ISO 13485, there are substantive gaps to address before the next FDA Form 483 arrives.

This post created by and appeared first on Cloudtheapp

FMEA (Failure Mode and Effects Analysis) is a structured, team-based method for identifying ways a product, process, or system can fail, understanding the consequences of each failure, and deciding which failures warrant action before they reach customers or regulators.

The method originated in the U.S. military in 1949 under MIL-P-1629, moved into NASA in the 1960s during the Apollo program, entered automotive production lines in the 1970s through Ford, and now sits at the center of quality and risk management requirements across FDA-regulated industries, automotive supply chains, and IEC-governed electrical systems.

For quality engineers and compliance teams, FMEA answers a specific question: where in this design or process is the risk most concentrated, and what are we going to do about it?

The Three Types of FMEA

The FMEA framework applies to different points in the product and process lifecycle. Understanding which type you need matters before you start.

Design FMEA (DFMEA) examines a product design before it goes to manufacturing. The team asks what could go wrong with each component, subassembly, or system function, and whether those failures would harm the end user, cause the device to malfunction, or create a regulatory compliance issue.

Process FMEA (PFMEA) shifts the analysis to manufacturing and assembly operations. Here, the failure modes involve process steps — incorrect torque, contaminated materials, misconfigured equipment — rather than component failures. PFMEA is where most production quality teams spend their time.

System FMEA takes a higher-level view, examining how subsystems interact and where system-level failures emerge from combinations of individual components that each function normally in isolation but produce unexpected behavior together.

Medical device manufacturers typically run DFMEA during design and development, PFMEA during process validation, and sometimes both together when design and manufacturing choices interact closely.

How Severity, Occurrence, and Detection Ratings Work

Every FMEA assigns three scores to each failure mode.

Severity (S) rates how bad the consequence would be if the failure occurred, on a scale of 1 to 10. A severity of 1 means the failure is barely noticeable. A severity of 9 or 10 means the failure causes patient harm, a regulatory violation, or loss of life. Severity addresses effect — it says nothing about likelihood.

Occurrence (O) estimates how often the failure mode is expected to happen, also on a 1-to-10 scale. Teams base this on historical data, process capability indices, or engineering judgment. An occurrence of 1 means the failure is almost impossible. A 9 or 10 means failures are likely to occur repeatedly in production.

Detection (D) rates how likely it is that existing controls will catch the failure before it reaches the customer. A low detection score (1-2) means your current controls will almost certainly catch this failure. A high detection score (8-10) means the failure will likely go undetected.

In the classic approach, these three numbers multiply together to produce a Risk Priority Number (RPN): RPN = S x O x D. RPNs range from 1 to 1,000. Teams set threshold values — often around 100-125 — and assign corrective actions to any failure mode above the threshold.

RPN vs. Action Priority: The AIAG-VDA 2019 Shift

The RPN method has a well-known flaw. A failure mode with a Severity of 10, an Occurrence of 1, and a Detection of 1 produces an RPN of just 10. Under classic FMEA, that failure mode might receive no action. But a severity of 10 means catastrophic harm. The RPN calculation can obscure the most dangerous failure modes by treating all three factors as equals.

The 2019 AIAG-VDA FMEA Handbook, produced jointly by the Automotive Industry Action Group and Verband der Automobilindustrie, addresses this directly by replacing RPN with Action Priority (AP). AP uses a structured lookup table in which Severity always comes first. Any failure mode with a Severity of 9 or 10 gets an Action Priority of High regardless of its Occurrence and Detection scores. The table then uses Occurrence and Detection as secondary modifiers to determine whether a lower-severity failure mode is High, Medium, or Low priority.

IEC 60812:2018, the general-purpose FMEA standard published by the International Electrotechnical Commission, still recommends the RPN approach but provides detailed guidance on how to score each dimension consistently and how to interpret RPN results in context. Teams working in electrical systems, medical devices outside the automotive supply chain, and general manufacturing most commonly reference IEC 60812:2018 for process structure.

For teams that still use RPN: the number alone never drives the decision. What matters is whether a failure mode warrants action, and a severity of 9-10 always does — regardless of what the multiplication produces.

ISO 14971 and What FDA Expects from Risk Management

ISO 14971:2019, "Medical Devices — Application of Risk Management to Medical Devices," is the international standard that governs risk management for medical devices. FDA recognizes it as a consensus standard and references it in the Quality Management System Regulation (QMSR).

FMEA fits within ISO 14971 as a risk analysis tool, but ISO 14971 asks for more than an FMEA spreadsheet. The standard requires a complete Risk Management File that covers:

• A risk management plan defining scope, responsibilities, and review criteria
• Risk analysis documenting identified hazards and their causes
• Risk evaluation determining which risks require reduction
• Risk controls with implementation evidence
• Evaluation of residual risk after controls are applied
• A benefit-risk determination for residual risks that cannot be reduced further
• Post-market surveillance data feeding back into the risk file

An FMEA can satisfy the risk analysis requirement inside ISO 14971, but it cannot substitute for the full file. Teams that submit only an FMEA without a risk management plan and without post-control evaluation regularly generate FDA Form 483 observations during device inspections.

Under the QMSR, which replaced the old 21 CFR Part 820 Quality System Regulation on February 2, 2026, FDA aligned its device quality requirements with ISO 13485:2016. This alignment brings ISO 14971's risk management approach directly into the FDA regulatory framework. Under QMSR, risk management is expected to run throughout the product lifecycle — design, production, post-market monitoring — rather than being treated as a pre-submission checklist item.

FDA inspection findings since the QMSR effective date have consistently flagged companies where risk management files are incomplete, where FMEAs have not been updated after design changes, and where post-market complaint data has not fed back into the risk register. The FDA's risk management guidance documents describe FMEA as appropriate for systematic failure analysis but emphasize that the output must connect to documented control decisions and post-market data loops.

Running an FMEA: The Six-Step Process

Most teams follow a structured process regardless of which standard they are working under.

Step 1: Define the scope. Determine whether this is a DFMEA, PFMEA, or System FMEA, and document what is in and out of scope. For a DFMEA, this typically means a functional block diagram of the device. For a PFMEA, it starts with a detailed process flow diagram.

Step 2: Identify failure modes. For each function or process step, ask what could go wrong. Document every potential failure mode — not just the ones the team considers likely. Teams that filter failure modes at this stage produce incomplete FMEAs that miss the failures that eventually reach customers.

Step 3: Analyze effects and causes. For each failure mode, document the effects on the user or the next process step, and identify the root cause or mechanism that could produce the failure. Vague cause statements like "operator error" or "material variation" do not support actionable controls.

Step 4: Rate Severity, Occurrence, and Detection. Apply the scoring criteria from your applicable standard consistently across the team. Rating calibration sessions at the start of a new FMEA reduce inter-rater variability and produce more defensible scores during audits.

Step 5: Prioritize and assign actions. Use RPN thresholds or the Action Priority table to identify which failure modes need action. Document the specific action, owner, and due date. An action field that reads "monitor" is a deferral, not an action.

Step 6: Verify and update. After implementing controls, re-score Occurrence and Detection. Severity rarely changes after a design fix unless the failure mode itself changed. Document the revised scores. An FMEA that still shows pre-control scores is an incomplete document.

Where FMEAs Break Down in Practice

Most FMEA problems in regulated environments come down to three patterns.

The first is treating the FMEA as a one-time submission artifact. Teams complete the analysis before design freeze, file it, and never return to it. When a change is made 18 months later, the FMEA does not reflect the current design. During a device inspection, investigators ask to see design change records alongside the FMEA. When the two do not match, that becomes an audit finding.

The second is disconnecting the FMEA from deviation CAPA records. When a failure mode identified in the FMEA actually occurs in production, the CAPA that follows should reference the FMEA entry. The root cause investigation should either confirm the FMEA's predicted cause or update it. FMEAs and CAPA systems maintained in separate, unlinked spreadsheets rarely stay synchronized.

The third is poor detection scoring. Teams routinely underestimate detection difficulty, assigning low scores to controls that are actually periodic spot checks or visual inspections. When a failure mode with a detection score of 2 escapes to the field and generates a complaint, investigators ask to see the detection control. What they often find is a quarterly audit that did not run in the quarter the failure occurred.

Managing FMEA in a QMS

Maintaining FMEA documents across design revisions, process changes, and post-market data updates requires a quality system that treats the FMEA as a living document rather than a static attachment.

This means version control for every FMEA revision, documented approvals when scores or actions change, links between FMEA records and design change requests, and automated notifications when a related CAPA opens that matches a documented failure mode.

Teams working in spreadsheets handle this through manual file management, which produces version control gaps and broken links between documents. When the same FMEA analysis lives in an electronic QMS with direct connections to design controls, change management records, and CAPA workflows, the update burden drops and the audit trail is automatic.

Cloudtheapp's FMEA application connects risk analysis directly to design controls, change management, and CAPA records within a single platform. When a design change request opens, the linked FMEA receives a notification for review. When a CAPA references a failure mode from the FMEA, the connection is documented and searchable. To see how this works in a live system, request a demo at cloudtheapp.com/demo/.

The Document That Defines Your Risk Posture

The FMEA table is the output. The analysis is the work, and the analysis requires a cross-functional team, structured facilitation, honest scoring, and a commitment to updating the file when new information arrives.

For quality engineers building or auditing a risk management program, the questions that matter: Does the FMEA reflect the current design? Do its high-priority failure modes have documented controls with implementation evidence? Does your post-market complaint data have an explicit pathway back into the risk file?

A well-maintained FMEA is among the most useful documents in a design file during a regulatory inspection. A stale one is among the most damaging.

This post created by and appeared first on Cloudtheapp

Selecting QMS software for a medical device company carries stakes that do not exist in other industries. The wrong system creates compliance gaps that surface during FDA inspections, delays 510(k) Submission timelines, and exposes the organization to FDA Form 483 observations that can halt production and distribution. The right system becomes the operational backbone that connects design controls, CAPA, document management, training, supplier oversight, and audit readiness into a single source of truth that holds up under regulatory scrutiny.

This guide covers what medical device QMS software must do differently from general-purpose quality tools, the eight features every platform needs to have before you evaluate it seriously, the questions that separate capable vendors from the rest, and the common selection mistakes that set quality teams back by months.

Why Medical Device QMS Software Is Different

A medical device quality management system is not simply a document repository with workflow automation added on top. The regulatory requirements for medical device manufacturers are specific, non-negotiable, and enforced through inspections that can result in consent decrees, import bans, and mandatory recalls.

Medical device companies operate under three primary quality frameworks simultaneously. FDA 21 CFR Part 820, now formally designated the Quality Management System Regulation (QMSR) as of February 2, 2026, sets the baseline for all manufacturers selling devices in the United States. ISO 13485:2016 is the international standard for medical device quality systems, required for CE marking in Europe and recognized across most major global markets. The EU Medical Device Regulation (EU MDR 2017/745) adds post-market surveillance, clinical evaluation, and Unique Device Identification requirements on top of that baseline.

The QMSR that took effect in February 2026 formally incorporated ISO 13485:2016 by reference into 21 CFR Part 820. This means FDA now conducts inspections using the inspection program described in the updated Compliance Program 7382.850, which aligns much more closely with ISO 13485 audit expectations. A quality team that understood the old QSR but has not updated its systems and processes for the QMSR faces real compliance risk in every FDA inspection conducted from February 2026 onward.

Generic quality management platforms built for manufacturing or general enterprise use cannot satisfy these requirements out of the box. Medical device QMS software must address design controls, device-specific risk management under ISO 14971, Design History File (DHF), Device Master Record (DMR), and Device History Record (DHR) requirements, 21 CFR Part 11 electronic records and signature compliance, and computer system validation requirements. These are not optional modules to add later. They are baseline requirements that determine whether the system is fit for regulated medical device use at all.

The 8 Non-Negotiable Features for Medical Device QMS Software

1. Design Controls With DHF, DMR, and DHR Management

Design controls are the foundation of medical device product development compliance. FDA 21 CFR Part 820.30 and ISO 13485 Section 7.3 both require a structured, documented design and development process that includes design inputs, design outputs, design reviews, verification, validation, and design transfer.

The QMS must support the creation and maintenance of the Design History File, which documents the complete design and development history of the device. It must also support the Device Master Record, which contains the approved specifications, drawings, procedures, and instructions for manufacturing the device, and the Device History Record, which captures the actual production records demonstrating that each unit was manufactured according to the DMR.

A QMS that manages these three document sets in isolation from CAPA, risk management, and change control creates documentation silos that will not hold up under inspection. The system should link design verification and validation records directly to the relevant CAPA outcomes, design changes, and risk assessments so that the full design decision history is traceable without manual reconstruction.

2. Document Control With Electronic Records and Signatures Under 21 CFR Part 11

Medical device manufacturers are required to maintain controlled documents covering manufacturing procedures, quality plans, test methods, specifications, and work instructions. Every document must have a defined owner, a review and approval workflow, a version history, and a retention schedule aligned with regulatory requirements.

The audit trail for every document action, including creation, review, approval, revision, and retirement, must meet 21 CFR Part 11 requirements. That regulation governs electronic records and electronic signatures used in FDA-regulated activities. It requires that electronic signatures be unique to one individual, that they cannot be reused or reassigned to another person, and that each signature be linked to a specific record that identifies the signer, the date and time of the signature, and the meaning of the signature.

A QMS that uses a generic document approval workflow without Part 11-compliant electronic signature controls creates records that FDA investigators can challenge as invalid. Every document action in the system must be captured in a tamper-evident, time-stamped audit trail that the system generates automatically and cannot be edited by any user.

3. CAPA Management With Structured Root Cause Investigation

Deviation CAPA is consistently among the most frequently cited areas in FDA audits of medical device manufacturers. CAPA processes that are reactive, undocumented, or disconnected from complaints, nonconformances, and audit findings produce audit finding observations that signal systemic quality system weakness to FDA investigators.

The QMS must support a CAPA workflow that captures the nonconformance or deviation trigger, requires a root cause investigation using structured methodologies (such as fishbone analysis, 5-Why, or fault tree analysis), documents the corrective and preventive actions defined, tracks implementation with responsible owners and due dates, and verifies effectiveness through a documented verification step after implementation.

CAPA records must be linked to the originating source, whether that is a complaint, an internal audit finding, a deviation, a supplier issue, or a post-market surveillance signal. When an FDA investigator pulls a CAPA during an inspection, they expect to see a complete chain from the trigger event through investigation, action, and verified effectiveness. A QMS that stores CAPA records in isolation from the events that generated them forces manual reconstruction of that chain, which is a reliability risk during inspections.

4. Risk Management Aligned With ISO 14971

ISO 14971 is the international standard for the application of risk management to medical devices. It requires that manufacturers establish, document, and maintain an ongoing risk management process covering hazard identification, risk estimation, risk evaluation, risk control, and residual risk assessment throughout the device lifecycle.

The QMS must support the creation and maintenance of a risk management file that links risk assessments to device design versions, production processes, and post-market data. A Risk Register that tracks identified hazards, their probability and severity scores, the risk controls applied, and the residual risk status after controls are in place must be maintained and updated throughout the product lifecycle, not just during initial design.

Risk management is not a one-time activity completed before the 510(k) submission. Post-market surveillance data, complaint trends, and field performance information must feed back into the risk management process. A QMS that supports risk management as a closed-loop process connected to post-market data, CAPA outcomes, and design changes gives the manufacturer a defensible, audit-ready risk management file that satisfies both FDA and EU MDR requirements.

5. Supplier Quality Management

Medical device manufacturers are responsible for the quality of components and services purchased from suppliers, even when those suppliers are not themselves FDA-registered. FDA 21 CFR Part 820.50 and ISO 13485 Section 7.4 both require that manufacturers establish and follow procedures for the evaluation and selection of suppliers, the definition of purchasing requirements, and the verification of purchased product.

Supplier Quality Management (SQM) within the QMS must support supplier qualification, including the maintenance of an approved supplier list, quality agreements, supplier audits, and performance monitoring. The system must also support Process Audit scheduling and documentation for critical suppliers, with findings linked back to CAPA and supplier re-evaluation workflows.

A QMS that manages suppliers in a separate spreadsheet or standalone database from the rest of the quality system creates a data integrity gap. Supplier deviations, audit findings, and incoming inspection failures must link directly to CAPA and change control records in the same system where all other quality events are managed.

6. Audit Management With Observation Tracking

Internal audits are a mandatory element of both 21 CFR Part 820 and ISO 13485. The QMS must support audit planning, audit scheduling, checklist configuration for different audit types, the documentation of audit findings with severity classifications, the assignment of findings to CAPA or corrective action workflows, and the tracking of finding closure.

The system should support both internal quality audits and supplier audits from the same interface, with consistent finding documentation and follow-up tracking. Audit reports must be version-controlled documents that satisfy the same document control requirements as all other controlled quality records.

FDA investigators reviewing the audit program during an inspection look specifically at whether audit findings are being closed systematically and whether the same types of findings recur across multiple audit cycles. A QMS that makes this trending analysis easy gives the quality team visibility into systemic gaps before an inspector identifies them first.

7. Training Management With Role-Based Qualification Records

Trained and qualified personnel are a requirement of both 21 CFR Part 820 and ISO 13485. Training records are a standard inspection request. The QMS must support the definition of role-based training requirements, the assignment of training tasks to individuals, the capture of training completion with electronic acknowledgment, and the tracking of training currency for procedures that require periodic retraining.

When a new document version is released, the system should automatically trigger training assignments for all personnel whose roles require training on that procedure. Training completion records must link to the specific document version that was trained on, so that during an inspection, the quality team can demonstrate exactly which personnel were trained on which version of a procedure at what point in time.

8. Pre-Validated Computer System With IQ/OQ/PQ Documentation

Computer system validation is a direct requirement of 21 CFR Part 820 and 21 CFR Part 11 for any software system used to create, modify, maintain, archive, retrieve, or transmit electronic records in a regulated medical device quality system. The cost and resource burden of validating a QMS platform from scratch can be significant, particularly for small and mid-size medical device companies.

A QMS platform that ships with a pre-validated state and provides a complete validation package, including Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) documentation for every platform update, removes this burden from the customer's quality team. The manufacturer takes responsibility for maintaining the validated state of the platform, and the customer inherits that validation package with each update rather than managing validation as an ongoing internal project.

This is not a minor convenience. For a medical device company with a lean quality team, managing CSV for a QMS platform as an ongoing internal project can consume hundreds of person-hours per year. A pre-validated SaaS platform with vendor-supplied validation packages converts that cost from a variable internal burden to a predictable element of the vendor relationship.

What Separates Good QMS Software From Great QMS Software

Once a platform meets all eight baseline requirements above, the differentiators come down to configurability, integration capability, scalability, and the total cost of compliance over the product lifecycle.

Configurability without coding. Medical device companies have processes that do not match generic templates. The QMS must be configurable to reflect the company's actual workflows, approval hierarchies, and document taxonomy without requiring custom development for every adjustment. Platforms that require vendor professional services for every workflow change create ongoing cost and dependency that constrains the quality team's ability to keep the system aligned with business processes.

Integrated applications across the full quality system. A QMS that connects CAPA to complaints, complaints to post-market surveillance, post-market surveillance to risk management, and risk management to design changes provides something that siloed systems cannot: a traceable record of how quality data flows through the system and influences decisions. This traceability is what FDA investigators and ISO auditors are looking for when they assess whether a quality system produces continuous improvement.

Process Change Notification and change control. Every change to a medical device, its manufacturing process, or its quality system procedures must be evaluated for regulatory impact before implementation. The QMS must support a formal change control process that captures the nature of the change, the risk assessment of its impact, the required approval authorities, the validation or verification activities required, and the regulatory filing implications, including whether the change requires a 510(k) supplement or PMA supplement submission.

Scalability from startup to commercial manufacturer. A medical device startup entering its first design controls activities has different QMS scope needs than a commercial manufacturer managing multiple device families across multiple facilities. The platform should be able to serve both without requiring a system replacement as the company grows. Switching QMS platforms mid-development or mid-production is one of the highest-risk quality system transitions a medical device company can undertake.

FDA Registration and post-market surveillance support. Commercial medical device manufacturers must maintain current FDA establishment registration and device listing. The QMS should support the documentation workflows connected to regulatory submissions, facility registration maintenance, and post-market surveillance reporting that keeps the manufacturer current with its FDA obligations.

10 Questions to Ask Every QMS Vendor

Before committing to any eQMS platform, these are the questions that separate capable vendors from those who will create problems for your quality system later.

1. Is the platform pre-validated, and what does the validation package include? Ask for a copy of the validation summary report. Confirm it covers IQ, OQ, and PQ, and ask how validation is maintained across platform updates.

2. Does the system support 21 CFR Part 11 electronic records and signatures natively? Confirm that electronic signatures are unique to individuals, linked to specific records with timestamp and meaning captured, and that the audit trail is system-generated and tamper-evident.

3. How does the system handle design controls? Confirm support for DHF, DMR, and DHR management, and ask how these records link to CAPA, risk management, and change control in the same system.

4. How is the CAPA process configured, and does it link to complaint and audit data? Confirm that CAPAs can be opened from multiple source types and that effectiveness verification is a defined, trackable step.

5. What is the computer system validation approach, and how often does it need to be repeated? A pre-validated SaaS platform that maintains validation across updates is fundamentally different from a system that requires customer-led validation for every change.

6. How does the platform support ISO 14971 risk management? Confirm that the risk management application supports the full ISO 14971 lifecycle and links risk assessments to post-market surveillance data and CAPA outcomes.

7. What are the implementation timeline and resource requirements? Confirm the typical time from contract signature to a validated, production-ready deployment. Ask for references from medical device companies of similar size and product complexity.

8. How does the system handle multi-site deployments? Confirm whether the platform supports multiple facilities under a single quality system or requires separate instances per site.

9. What happens to your data if you stop using the platform? Confirm data export formats, export completeness (including audit trails and attachment files), and the timeline and format for data return on contract termination.

10. What does the vendor's upgrade and maintenance model look like? Confirm whether updates are included in the subscription, whether they require re-validation, and who is responsible for managing each update through the validated state.

Common Medical Device QMS Selection Mistakes

Selecting based on price alone. The cheapest QMS option in the medical device space is almost always the most expensive option when hidden costs are factored in: custom development, ongoing validation work, consultant fees for compliance gaps discovered during inspection preparation, and the cost of switching platforms when the first choice proves inadequate.

Choosing a generic quality platform rather than one built for regulated industries. A QMS that meets ISO 9001 requirements for a general manufacturer does not meet the design control, 21 CFR Part 11, and risk management requirements for a medical device manufacturer. The gap between these two regulatory environments is wide, and attempting to close it with workarounds adds technical debt to the quality system that regulators can identify during an inspection.

Deferring the QMS decision until after the first 510(k) submission. Design controls, risk management, and CAPA records generated during the development phase are part of the regulatory submission and inspection evidence package. Companies that manage early-stage development in spreadsheets and migrate to a formal QMS after submission face the challenge of recreating that early-stage documentation trail in the new system, which carries data integrity risk.

Underestimating the validation burden for non-validated platforms. A platform that is not pre-validated requires the quality team to execute computer system validation internally before it can be used to manage regulated records. This is a significant resource commitment that many quality teams underestimate until they are already committed to a vendor contract.

Ignoring scalability requirements. A system that works well for a 10-person startup may not scale to a 200-person commercial manufacturer without significant reconfiguration, re-validation, or replacement. Evaluating the platform against the organization's 3-year and 5-year growth trajectory during the selection process avoids a forced migration at a critical production or submission milestone.

How Cloudtheapp Supports Medical Device QMS Requirements

Cloudtheapp's AI-powered, no-code eQMS provides medical device companies with a pre-validated, FDA 21 CFR Part 820 (QMSR) and ISO 13485-compliant quality management platform built for the full device lifecycle. The platform's 45+ pre-configured applications cover every element of the medical device quality system: design controls, document control, CAPA, risk management, supplier qualification, audit management, training management, complaint handling, change control, and post-market surveillance.

Every platform update ships with a complete validation package covering IQ, OQ, and PQ documentation, so Cloudtheapp's quality team manages the computer system validation burden rather than passing it to customers. The platform's built-in audit trail and 21 CFR Part 11-compliant electronic signature capabilities are built into the core architecture, not added as optional modules.

Cloudtheapp's no-code configuration tools allow quality teams to adapt workflows, forms, and approval processes to their specific operations without vendor professional services involvement or re-validation. The same platform that a 15-person startup uses to manage Phase 1 device development scales to support a commercial manufacturer with multiple device families and global distribution without system replacement.

Book a free demo to see how Cloudtheapp's pre-validated medical device eQMS supports FDA QMSR, ISO 13485, and EU MDR compliance from first design controls through commercial manufacturing.

Conclusion

Medical device QMS software selection is a decision with a long tail. The platform you choose today shapes the audit readiness, regulatory submission quality, and inspection outcomes of the next 5-10 years of the organization's compliance history. Getting it right requires evaluating against the specific requirements of 21 CFR Part 820 (QMSR), ISO 13485, and the other frameworks that govern your specific markets, not against generic quality management benchmarks.

The eight features covered in this guide are the baseline. Every platform you evaluate seriously must demonstrate pre-validation, 21 CFR Part 11 compliance, design control support, CAPA with root cause investigation, ISO 14971 risk management, supplier qualification, audit management, and training management before any other factors influence the decision.

Beyond the baseline, the differentiators that produce the most long-term value are configurability, integrated applications, scalability, and a vendor relationship built on compliance expertise rather than generic software support.

This post created by and appeared first on Cloudtheapp

Quality control software handles inspection, testing, and defect detection at specific points in a production or service process. Quality management software (QMS) governs the entire quality system — documents, CAPAs, audits, training, and regulatory compliance. In regulated industries, these functions are most effective — and most defensible during inspections — when unified in one pre-validated platform. Cloudtheapp delivers both in a single AI-powered, no-code eQMS.

What Is Quality Control Software?

Quality control software refers to applications that support the inspection, testing, measurement, and defect-detection activities at specific points in a production or service delivery process.

In practice, this includes:

• Incoming material inspection management
• In-process and final product inspection recording
• Out-of-specification (OOS) and out-of-trend (OOT) detection
• Nonconformance and defect logging
• Lab testing and results management
• Calibration and measurement system management
• Statistical process control (SPC) and measurement data capture

Quality control is a detection and verification function. It answers the question: does this product, batch, or process step meet its specifications?

Quality Control Software vs Quality Management Software: Key Differences

The terms appear interchangeably in many vendor marketing materials, but they describe different scopes of work.

Quality control software focuses on the real-time activities of detecting, recording, and responding to quality issues at the point of occurrence — in the lab, on the production line, at incoming inspection, or in the field.

Quality management software (QMS) covers the full quality system: document control, change management, CAPA, audit management, training, supplier qualification, risk management, regulatory compliance, and the reporting and analytics that connect all of them.

In regulated industries — pharmaceutical manufacturing, medical device production, food and beverage, biotech, and industrial manufacturing — quality control activities cannot operate independently from quality management. A nonconformance found during incoming inspection generates a deviation report. That deviation may trigger a CAPA. The CAPA requires a root cause investigation. The corrective action requires a document control update and a training assignment.

When quality control software and QMS software are separate systems, the connections between these steps are manual, fragile, and consistently cited by FDA investigators as data integrity risks.

Why Regulated Industries Need Unified Quality Control and QMS Capabilities

The Data Integrity Problem with Disconnected Systems

FDA’s data integrity framework — ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available) — applies to every quality record in a regulated operation. When a quality control result exists in one system and the investigation triggered by that result exists in another, the ALCOA+ chain breaks.

Where this breaks in practice:

An OOS result recorded in a standalone lab system triggers an investigation in a separate QMS module. The audit trail on the investigation does not include the original result record’s creation metadata.

A nonconforming lot is recorded in a quality control database. The disposition decision happens in email. Neither system holds a complete record of the other.

Calibration failures flag in one system. Results produced by that instrument during the out-of-tolerance period exist in a separate system — with no automatic connection between them.

Each gap represents individual compliance exposure. Together, they form the pattern that produces FDA warning letters.

Inspection Readiness Requires Connected Quality Data

When an FDA investigator arrives, a typical request is: “Show me every nonconformance related to Supplier X in the last 18 months — including the investigation records and corrective actions.” If quality control data lives outside the QMS, assembling that answer takes days rather than minutes.

Inspection-ready organizations run quality control records inside their quality system — not alongside it. The ability to produce a complete evidence chain from a quality event through investigation to corrective action in minutes is the operational difference between a confident inspection response and a documentation scramble.

Risk Management Requires Quality Control Input

ISO 13485 Section 8.2.1, FDA QMSR, and ISO 9001:2015 all require that post-market and operational quality data feed back into the risk management process. Field complaint trends, OOS recurrence rates, supplier nonconformance patterns, and in-process defect data are the primary inputs to a meaningful risk register update.

If quality control data cannot flow automatically into the QMS risk management workflow, this feedback loop operates manually at best and is absent at worst.

What Quality Control Software Must Do in Regulated Industries

Nonconforming Material Management

Nonconforming material management requires classification, documented containment, disposition with traceable approval authority, and a linkage to CAPA when recurrence risk exists. A quality control system that records a defect without enforcing this workflow creates a compliance gap that appears consistently in FDA Form 483 observations.

Disposition decisions — use-as-is, rework, scrap, return-to-supplier — must be documented with justification, an identified approving authority, and an audit trail capturing who made the decision and when.

Out-of-Specification Investigation Management

For pharmaceutical and biotech manufacturers, OOS investigations follow a defined Phase I/Phase II framework per FDA’s 2006 OOS guidance. Phase I is a laboratory assessment only — checking instrument function, sample preparation, and analyst error. Phase II is a manufacturing investigation. A quality control system must enforce this sequence. Platforms that allow Phase II retesting before Phase I is documented create a data integrity violation, not a quality investigation.

Lab Testing and Results Management

Lab results must carry computer-generated timestamps, link to the instrument that produced them, connect to the analyst qualification record for the analyst who performed the test, and be captured in a tamper-evident system. A results management approach that operates in spreadsheets or a standalone LIMS creates the traceability gaps that generate warning letters.

Calibration and Measurement System Management

The metrology program — instrument qualification, calibration scheduling, out-of-tolerance response, and results traceability — must connect to the quality records produced by those instruments. A calibration failure should automatically flag affected results produced during the out-of-tolerance period and trigger a defined investigation workflow — not wait for a manual review.

Incoming Inspection

Incoming inspection records must link to supplier qualification profiles, sampling plans, and nonconformance records. When a supplier’s incoming inspection failure rate crosses a defined threshold, the supplier risk score should update automatically. A supplier risk tier assigned at onboarding and never revisited is not a risk management program.

Statistical Process Control and Trend Analysis

SPC capabilities allow quality teams to identify process trends before defects occur. Control charts, process capability indices (Cp, Cpk), and out-of-trend alerts connected to the production record are standard expectations for regulated manufacturing — particularly under FDA QMSR, which emphasizes continued process verification as an ongoing quality program, not a one-time post-approval exercise.

How to Evaluate Quality Control Software for Regulated Industries

These criteria separate functional platforms from checkbox solutions:

Integration with the QMS. Does the quality control system share a single validated environment with document control, CAPA, supplier quality, and audit management — or does it require API integrations and separate validation efforts? The integration gap is where compliance failures grow.

21 CFR Part 11 compliance. Every quality control record — inspection result, OOS finding, calibration log, lab result — must satisfy 21 CFR Part 11 electronic records requirements, including system-generated audit trails on every entry, change, and deletion.

Pre-validated platform. Quality control software used in regulated industries is subject to FDA Computer Software Assurance (CSA) requirements. A vendor that supplies validation documentation with every update eliminates the obligation to build it from scratch.

Configurable inspection and testing workflows. Every regulated operation runs quality control differently. A platform that requires professional services to add an inspection type or modify a sampling plan creates a bottleneck that compounds over time.

Automated escalation for quality signals. Overdue calibrations, OOS results without completed investigations, and nonconformances aging past their due dates should all generate automatic escalations with defined owners and due dates — not require manual monitoring.

Complete traceability. From a single quality control event, a user should be able to trace from the result to the instrument, to the analyst qualification, to the lot record, to the supplier, to the risk register — within a single system and a single audit trail.

How Cloudtheapp Delivers Unified Quality Control and QMS Capabilities

Cloudtheapp includes quality control capabilities as native components of a fully integrated, pre-validated eQMS — not as an add-on module requiring separate configuration and validation.

For regulated manufacturers and life sciences organizations, Cloudtheapp provides:

Lab Testing and Management directly inside the quality system — with instrument traceability, analyst qualification linkage, OOS investigation workflows, and a system-generated audit trail on every result.

Inspections and Nonconforming Material management with automated classification, containment documentation, disposition workflows, and CAPA linkage — configured to your process without code.

Calibration and Maintenance management connected to production records and lab results, with automated requalification scheduling and out-of-tolerance escalation triggers.

Out-of-Specification investigation workflows that enforce the Phase I/Phase II framework required by FDA guidance — with timestamped action records and automatic CAPA linkage when Phase II confirms a genuine product or process failure.

Built-in analytics and statistical process control with real-time trend data accessible to quality leadership, not compiled manually once per quarter.

Supplier Qualification Management that connects incoming inspection results directly to supplier risk scores and SCAR workflows — automatically, every time.

All of this runs in one pre-validated environment, on a single audit trail, with no integration gaps between quality control and quality management functions.

If your current quality control approach involves separate systems, spreadsheet tracking, or manual connections to your QMS, the compliance exposure is real — and the inspection burden is avoidable.

Request a free demo at cloudtheapp.com to see how unified quality control and QMS capabilities work in one platform.

Frequently Asked Questions

What is the difference between quality control and quality assurance software?

Quality control is the activity of detecting defects and verifying conformance at specific process points. Quality assurance is the broader discipline of ensuring the processes that produce quality outcomes are properly designed, controlled, and continuously improved. In regulated industries, both functions are managed through a Quality Management System — making the distinction primarily functional rather than organizational.

Does quality control software need to be FDA-validated?

Yes. Any software used in regulated production or quality management activities is subject to FDA Computer Software Assurance (CSA) requirements. This requires documented assurance activities proportional to the risk of the software’s intended use.

Can a QMS replace dedicated quality control software?

A modern, integrated eQMS with native quality control modules — lab testing, inspections, nonconforming material management, calibration, and OOS management — can replace standalone quality control software while providing the regulatory traceability that separate systems cannot match.

Which industries use quality control software most heavily?

Pharmaceutical manufacturing, medical device production, biotech, food and beverage manufacturing, chemical production, automotive, and laboratory environments are the primary regulated industries with structured quality control requirements enforced by regulatory agencies including FDA, USDA, ISO certification bodies, and GFSI schemes.

The Bottom Line

Quality control software in regulated industries is only as effective as its connection to the broader quality management system. Inspection results that do not flow automatically into CAPA workflows, lab results that exist outside the validated audit trail, and calibration records that cannot link to affected test results are not quality control infrastructure — they are compliance liabilities.

The regulated companies that perform best during FDA and Notified Body inspections run quality control and quality management in one validated, connected system.

Cloudtheapp delivers that system — with AI-powered configurability, no-code workflow management, and pre-validated compliance for pharmaceutical, medical device, biotech, food and beverage, and manufacturing organizations.

Book a free demo at cloudtheapp.com to see how Cloudtheapp eliminates the gap between quality control and quality management.

This post created by and appeared first on Cloudtheapp